common.study.topics.clinical

Testing Experimental Medication in Healthy Subjects

common.study.values.description

Exploratory Evaluation of [11C]-NOP46

This is an open-label, single center design. In the first stage, five (5) healthy individuals will receive a microdose (10A?g) of [11C]-NOP46, immediately followed by whole body positron emission tomography (PET)/computed tomography (CT) to determine dosimetry and perform an initial safety evaluation of the radiotracer. If no toxicities develop, then the investigation will move to the second stage, in which thirty (30) patients with chronic pain will receive a microdose of [11C]-NOP46 followed by PET/CT of region of interests.

common.study.values.location

participant.ui.study.affiliations-map.online-study.header-virtual

participant.ui.study.affiliations-map.online-study.text

participant.ui.study.affiliations-map.legend.locations participant.ui.study.affiliations-map.legend.selected

common.study.values.methods

Pharmaceutical medication involved common.study.methods.has-drugs-yes
Patients and healthy individuals accepted common.study.methods.is-healthy-no

Drug - [11C]-NOP46

Subjects will receive a microdose (≤10 µg) of [11C]-NOP46.

Radiation - PET/CT scan

After subjects receive a microdose of [11C]-NOP46, whole body PET/CT scan(s) will be performed to determine dosimetry and perform an initial safety evaluation of the radiotracer in Stage 1 and region of interests in Stage 2.

participant.views.study.view.additional

participant.views.study.view.scientific-title

Exploratory Evaluation of [11C]-NOP46 Pharmacokinetics With Positron Emission Tomography (PET)

common.study.values.clinical-trial-id

NCT03705819

participant.views.study.view.id

dR61qd